Lamotrigine augmentation in premenstrual dysphoric disorder: a case report

Clin Neuropharmacol. 2013 Jan-Feb;36(1):31-3. doi: 10.1097/WNF.0b013e318279ee1f.


Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome, characterized by depressive, anxious, and somatic symptoms, associated to a significant reduction in social functioning and quality of life. Although selective serotonin reuptake inhibitors (SSRIs) and oral contraceptives show a substantial effectiveness in PMDD, a wide percentage of women affected by PMDD do not respond to those first-line treatments. We present the case of a 42-year-old woman, affected by a disabling form of PMDD, who partially responded to an SSRI treatment and significantly improved after an add-on therapy with lamotrigine. We therefore suggest that lamotrigine may be an efficacious and safe augmentation strategy in severe PMDD cases showing unsatisfactory or partial response to SSRI treatments.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Therapy, Combination
  • Female
  • Humans
  • Lamotrigine
  • Premenstrual Syndrome / diagnosis*
  • Premenstrual Syndrome / drug therapy*
  • Premenstrual Syndrome / psychology
  • Selective Serotonin Reuptake Inhibitors / administration & dosage*
  • Triazines / administration & dosage*


  • Serotonin Uptake Inhibitors
  • Triazines
  • Lamotrigine